Table 3. Univariate and multi-variate analysis of the clinicopathological and molecular features for OS in LUAD.

Clinicopathological parameters	Comparison reference	Univariate analysis		Multi-variate analysis
		Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
Age	< 65	Ref		Ref
	≥ 65	1.906 (1.079–3.366)	0.026	1.566 (0.838–2.926)a	0.159a
Gender	Male	Ref
	Female	1.176 (0.640–2.160)	0.602
Smoke	No	Ref
	Yes	1.577 (0.891–2.790)	0.118
Clinical Stage	IA	Ref	< 0.001	Ref	< 0.001a
	IB	1.058 (0.177–6.338)	0.951	0.907 (0.150–5.499)a	0.916a
	IIA	4.515 (0.934–21.817)	0.061	4.513 (0.919–22.164)a	0.064a
	IIB	6.102 (1.397–26.660)	0.016	4.278 (0.966–18.945)a	0.056a
	IIIA	19.666 (4.234–91.348)	< 0.001	13.101 (2.796–61.386)a	0.001a
	IIIB	10.963 (2.415–49.760)	0.002	6.050 (1.307–27.996)a	0.021a
Target therapy	Yes	Ref		Ref
	No	2.000 (1.129–3.542)	0.018	1.697 (0.934–3.083)a	0.083a
IL-1β level	Low	Ref		Ref
	High	3.818 (1.986–7.339)	< 0.001	3.166 (1.592–6.297)a	0.001a
TNF-α level	Low	Ref		Ref
	High	1.954 (1.101–3.466)	0.022	1.332 (0.730–2.431)a	0.350a
miR-144-3p level	Low	Ref		Ref
	High	0.427 (0.238–0.765)	0.004	0.365 (0.196–0.681)b	0.002b
Age	< 65	Ref
	≥ 65	0.649 (0.280–1.503)	0.307
Gender	Male	Ref
	Female	0.913 (0.375–2.224)	0.842
Smoke	No	Ref
	Yes	0.909 (0.384–2.153)	0.828
Clinical Stage	IA	Ref	0.039	Ref	0.221
	IB	2.830 (0.255–31.346)	0.397	3.088 (0.275–34.686)	0.361
	IIA	5.361 (0.626–45.921)	0.125	4.805 (0.550–41.949)	0.156
	IIB	9.739 (1.186–79.956)	0.034	8.430 (0.995–71.386)	0.050
	IIIA	17.498 (2.100–145.829)	0.008	13.287 (1.442–122.460)	0.022
	IIIB	19.248 (1.157–320.344)	0.039	14.606 (0.812–262.349)	0.069
IL-1β level	Low	Ref		Ref
	High	3.106 (1.218–7.917)	0.018	1.531 (0.503–4.657)	0.453
TNF-α level	Low	Ref
	High	0.810 (0.357–1.839)	0.615
miR-144-3p level	Low	Ref
	High	1.216 (0.533–2.777)	0.642

^aMultivatiate model including Age, Clinical Stage, Target therapy, IL-1β & TNF-α.

^bMultivatiate model including Age, Clinical Stage, Target therapy, miR-144-3p & TNF-α.